Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein
Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and
possesses great capacity to penetrate the retinal tissue, particularly in pathological circumstances characterized by
altered external or internal blood-retinal barrier.Bevacizumab has an optimal bio-efficacy based on inhibition of the
activity of Vascular Endothelial Growth Factor (VEGF). Nonetheless, despite its efficacy, here we describe the
adverse effects associated with intraocular injection of bevacizumab in a patient affected by retinal vein occlusion.
Case presentation: We present a case report of an 11-year old Caucasian malesubject affected by BRVO in his left
eye. The patient underwent an intra-vitreal (i.v.) injection of bevacizumab 100 (1.25 mg/0.05ml). After that, the
patient was monitored over time through a series of analyses including Ocular Coherence Tomography,
Fluorangiography, Bulbar Ultrasound, Angio MRI BCVA scores and Intra Ocular Pressure. Results: Immediately
after the i.v. injection, the patient experienced a strong and relentless pain radiating from the left ocular orbit, caused
by a serious and unexpected malignant glaucoma and phthisis bulbi. Furthermore, the patient did not show any sign
of improvement in visual function in the follow-up and at last required an ophthalmic prosthesisas a result of a subatrophic
and hypotonic eyeball. Conclusion: This case report suggests that i.v. injections of anti-VEGFs should be
considered wit
